BackCaliPharms Overview

CaliPharms Other Liabilities

Track CaliPharms's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

CaliPharms Other Liabilities History

Loading

CaliPharms vs. peers: Other Liabilities Comparison

Loading

CaliPharms Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CaliPharms (KGET) FAQ

CaliPharms (KGET) currently reports a other liabilities of $0 as of September 2014. In the prior-year period, the figure was $0. Use the charts on this page to explore CaliPharms's other liabilities history and peer comparisons.

CaliPharms's other liabilities changed from $0 to $0 (period ending September 2014). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CaliPharms reported $0 in other liabilities as of September 2014. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CaliPharms, and consider following KGET for alerts when major investors trade the stock.

CaliPharms is classified in the Industrials sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing KGET with unrelated industries.